Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Simons Foundation Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active matters are distributed across 2 distinct examiners and 2 distinct art units, indicating a diverse range of technical inquiries from the patent office. This distribution suggests that the company's patenting efforts in the biotechnology and pharmaceutical fields are being reviewed by multiple specialized groups, which may require a more varied prosecution strategy to address different examiner perspectives.
The busiest examiner for the portfolio is PETERS, ALEC JON, who is currently handling 1 busiest examiner pending office action. This 1 pending office action represents a portion of the company's total active workload. Because the 2 pending office actions are split between 2 distinct examiners, the company must manage separate dialogues within the Biotechnology & Pharmaceuticals sector. Practitioners should be prepared to address the specific technical standards of each of the 2 distinct art units involved to ensure that both pending matters move toward allowance. The outcome of the work handled by the busiest examiner will be a key component of the portfolio's overall success.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | SKELDING, ZACHARY S | 63d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017849 | COMBINATORIAL ANTIGEN RECOGNITION IN CANCER T CELL THERAPIES | PETERS, ALEC JON | 20d |
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | SKELDING, ZACHARY S | 63d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18017849 | COMBINATORIAL ANTIGEN RECOGNITION IN CANCER T CELL THERAPIES | PETERS, ALEC JON | 1641 | §103§112DP | Final Rejection | 20d | Pending | Jan 24, 2023 |
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | SKELDING, ZACHARY S | 1644 | §102§103 | Non-Final OA | 63d | Pending | Jun 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial